Correlation Between Bolt Biotherapeutics and Cadrenal Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bolt Biotherapeutics and Cadrenal Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bolt Biotherapeutics and Cadrenal Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bolt Biotherapeutics and Cadrenal Therapeutics, Common, you can compare the effects of market volatilities on Bolt Biotherapeutics and Cadrenal Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bolt Biotherapeutics with a short position of Cadrenal Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bolt Biotherapeutics and Cadrenal Therapeutics,.

Diversification Opportunities for Bolt Biotherapeutics and Cadrenal Therapeutics,

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Bolt and Cadrenal is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Bolt Biotherapeutics and Cadrenal Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cadrenal Therapeutics, and Bolt Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bolt Biotherapeutics are associated (or correlated) with Cadrenal Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cadrenal Therapeutics, has no effect on the direction of Bolt Biotherapeutics i.e., Bolt Biotherapeutics and Cadrenal Therapeutics, go up and down completely randomly.

Pair Corralation between Bolt Biotherapeutics and Cadrenal Therapeutics,

Given the investment horizon of 90 days Bolt Biotherapeutics is expected to under-perform the Cadrenal Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Bolt Biotherapeutics is 11.73 times less risky than Cadrenal Therapeutics,. The stock trades about -0.03 of its potential returns per unit of risk. The Cadrenal Therapeutics, Common is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  0.15  in Cadrenal Therapeutics, Common on September 13, 2024 and sell it today you would earn a total of  1,160  from holding Cadrenal Therapeutics, Common or generate 773233.33% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy96.77%
ValuesDaily Returns

Bolt Biotherapeutics  vs.  Cadrenal Therapeutics, Common

 Performance 
       Timeline  
Bolt Biotherapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Bolt Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Cadrenal Therapeutics, 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Bolt Biotherapeutics and Cadrenal Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bolt Biotherapeutics and Cadrenal Therapeutics,

The main advantage of trading using opposite Bolt Biotherapeutics and Cadrenal Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bolt Biotherapeutics position performs unexpectedly, Cadrenal Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cadrenal Therapeutics, will offset losses from the drop in Cadrenal Therapeutics,'s long position.
The idea behind Bolt Biotherapeutics and Cadrenal Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
CEOs Directory
Screen CEOs from public companies around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope